	US 11,981,896 B2
	p21 mRNA target areas for silencing
Noam Pilpel, Rehovot (IL); Yossi Ovadya, Rehovot (IL); Dina Raichlin, Rehovot (IL); Etti Katz-Kadosh, Rehovot (IL); Alaa Knany, Rehovot (IL); Ella Gillis, Rehovot (IL); Noam Borovsky, Rehovot (IL); Anastasia Shapiro, Rehovot (IL); and Ido Bachelet, Rehovot (IL)
Assigned to 1E Therapeutics Ltd., Rehovot (IL)
Filed by 1E Therapeutics Ltd., Rehovot (IL)
Filed on Jun. 28, 2023, as Appl. No. 18/342,806.
Application 18/342,806 is a continuation of application No. PCT/IL2021/051545, filed on Dec. 28, 2021.
Claims priority of provisional application 63/130,936, filed on Dec. 28, 2020.
Prior Publication US 2023/0357771 A1, Nov. 9, 2023
Int. Cl. C12N 15/113 (2010.01); A61P 35/00 (2006.01)

CPC C12N 15/113 (2013.01) [A61P 35/00 (2018.01); C12N 2310/14 (2013.01); C12N 2310/32 (2013.01)]

15 Claims

1. A DNAzyme molecule comprising the nucleic acid sequence set forth in any one of SEQ ID NOs: 18, 19, 20, 21, or 22 or a DNAzyme molecule comprising the nucleic acid sequence at least 80% identical to the nucleic acid sequence set forth in any one of SEQ ID NOs: 18, 19, 20, 21, or 22.